Navigation Links
New method yields potent, renewable human stem cells with promising therapeutic properties
Date:3/25/2014

New Rochelle, NY, March 24, 2014The curative and therapeutic potential of mesenchymal stem cells (MSCs) offers much promise, as these multipotent cells are currently being tested in more than 300 clinical trials in a range of diseases. A new, easier, and more reliable way to make large quantities of highly potent MSCs could accelerate progress toward their use in regenerative medicine, as described in an article in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Stem Cells and Development website.

Robert Lanza, MD and colleagues from Advanced Cell Technology (Marlborough, MA) and the David Geffen School of Medicine, UCLA (Los Angeles, CA), developed an innovative method for deriving MSCs from human embryonic stem cells (hESCs) through the use of a developmental precursor called the hemangioblast. They describe the technique and evidence of therapeutic efficacy using the hESC-MSCs to treat mouse models of lupus erythematosus and uveitis in the article "Mesenchymal Stem Cell Population Derived from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties."

"This new population of hESC-derived MSCs has a 30,000-fold greater proliferative capacity than bone marrow-derived MSCs," says Dr. Lanza, Chief Scientific Officer, Advanced Cell Technology. "In addition to being easy to derive in very large numbers, they are more youthful and live much longer." Dr. Lanza is Editor-in-Chief of BioResearch Open Access, a peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers that provides a rapid-publication forum for a broad range of scientific topics.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. A non-invasive, rapid screening method for Alzheimers disease
2. AZTI-Tecnalia develops a methodology for authenticating canned tuna species within 24 hours
3. Researchers warn against abrupt stop to geoengineering method
4. New NIST method evaluates response to oxidation in live cells
5. Caltech-developed method for delivering HIV-fighting antibodies proven even more promising
6. New method developed for ranking disease-causal mutations within whole genome sequences
7. GW receives up to $14.6 million to develop method to characterize security threats
8. New method increases supply of embryonic stem cells
9. Gold nanoparticles help to develop a new method for tracking viruses
10. Developing methods for building precise nanostructures
11. Big data: A method for obtaining large, phylogenomic data sets
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New method yields potent, renewable human stem cells with promising therapeutic properties
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) today announced ... Rodman & Renshaw, a unit of H.C. Wainwright ... representative of several underwriters, under which the underwriters have ... minimum of 2,105,264 shares of common stock of the ... 1,052,632 shares of common stock of the Company with ...
(Date:1/23/2017)...   Enteris BioPharma, Inc. , announced today the ... to leverage Enteris, proprietary and patented oral peptide ... oral formulation of one of Sanofi,s preclinical stage peptides. ... Officer and Executive Chairman of Enteris BioPharma, remarked, "Our ... value our Peptelligence platform program offers in the therapeutic ...
(Date:1/23/2017)... Township, PA (PRWEB) , ... January 23, 2017 ... ... P. Thomas has been appointed Vice President, Preclinical Safety and Senior Director, Safety ... University of Madras in India. , Dr. Thomas’ career as an academic ...
(Date:1/23/2017)... Utah (PRWEB) , ... January 23, 2017 , ... ... been named an INTERNET TELEPHONY Product of the Year Award winner for 2017. ... industry leader in unified communications solutions. In 2016, CallTower was awarded with the hosted ...
Breaking Biology Technology: